BioNTech: Successful Trials of mRNA Vaccine against Multiple Sclerosis

BioNTech: Successful Trials of mRNA Vaccine against Multiple Sclerosis

Publication date: Jan 12, 2021

GERMAN pharmacist BioNTech, which developed one of the approved covid-19 vaccines together with US-based Pfizer, announces successful trials of mRNA vaccine against multiple sclerosis.

The company has published the first data on the preclinical application of the principle behind its covid-19 vaccine to treat autoimmune diseases such as multiple sclerosis.

In a study published on Friday (January 8) in the journal Science, the company indicates that it has succeeded in developing an mRNA vaccine tested in -complex models of multiple sclerosis in mice” in which suppression of the disease has been detected.

Concepts Keywords
Antigen MRNA-1273
Antigens BioNTech
Autoimmune COVID-19 vaccine
Autoimmune Diseases Pfizer
Coronavirus Vaccines
Germany RNA vaccine
Global News RNA
Immune Suppression Medical research
Immunomodulation Health sciences
Immunosuppression Medicine
Johannes Gutenberg Immunosuppression
Mainz Cell Multiple sclerosis
Mice SARS
MRNA Disease
MRNAs Multiple Sclerosis
Multiple Sclerosis Pharmaceutical
Myelin
Neurodegenerative
Pfizer
Pharmaceutical Company
Pharmacist
Protein
SARS
Spanish
Spike
Vaccine

Semantics

Type Source Name
disease MESH Multiple Sclerosis
disease MESH autoimmune diseases
disease MESH development

Leave a Comment

Your email address will not be published. Required fields are marked *